COMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023 Post published:May 3, 2023 Post category:Press Release
The Top 5 Psychedelic Clinical Trials of 2022 Post published:May 3, 2023 Post category:2022 Year in Review
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology Post published:May 3, 2023 Post category:Press Release
atai Life Sciences to Participate in Upcoming May Investor Conference Post published:May 3, 2023 Post category:Press Release
Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial Post published:May 2, 2023 Post category:Press Release
PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease Post published:May 2, 2023 Post category:Press Release
American Medical Association to Issue First New Code for Psychedelic Therapies Post published:May 2, 2023 Post category:Press Release
Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19 Post published:May 2, 2023 Post category:Press Release
Psychedelic Bulletin #136: MindMed Collaborators Share Topline LSD for MDD Results; Oregon Issues Psilocybin Licences; UK Parliament to Discuss Psilocybin Rescheduling Post published:April 28, 2023 Post category:Psychedelic Bulletin
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting Post published:April 28, 2023 Post category:Press Release